Search research articles
Contact Us
Filters
Showing results (61-70 of 76) with videos related to
Page
of 8
Sort By:
The Oncologist
|
June 17, 2016
A Randomized Controlled Trial of a Nurse-Led Supportive Care Package (SurvivorCare) for Survivors of Colorectal Cancer
Michael Jefford, Karla Gough, Allison Drosdowsky, et al.
Current Problems in Cancer
|
August 23, 2020
Metastasectomy and BRAF mutation; an analysis of survival outcome in metastatic colorectal cancer
Thiru Prasanna, Rachel Wong, Timothy Price, et al.
BMC Public Health
|
August 26, 2025
Exploring the association between Cultural and Linguistic Diversity (CALD) on treatment and outcomes in pancreatic cancer: an analysis of PURPLE real-world registry data from an Australian population
Emma Sanderson, Belinda Lee, Nadia Ayres, et al.
European Urology
|
October 15, 2022
Emergence of BRCA Reversion Mutations in Patients with Metastatic Castration-resistant Prostate Cancer After Treatment with Rucaparib
Andrea Loehr, Arif Hussain, Akash Patnaik, et al.
Internal Medicine Journal
|
November 18, 2024
Real-world impact of pembrolizumab availability for deficient mismatch repair metastatic colorectal cancer
Matthew Loft, Vanessa Wong, Suzanne Kosmider, et al.
Asia-Pacific Journal of Clinical Oncology
|
July 14, 2022
Use and outcomes from neoadjuvant chemotherapy in borderline resectable pancreatic ductal adenocarcinoma in an Australasian population
Imogen Walpole, Belinda Lee, Jeremy Shapiro, et al.
Asia-Pacific Journal of Clinical Oncology
|
January 24, 2022
Impact of the evolution in RAS mutation analysis in Australian patients with metastatic colorectal cancer
Chia Yuen Chong, Azim Jalali, Hui Li Wong, et al.
The Oncologist
|
March 11, 2022
Complementary Medicine Use Amongst Patients with Metastatic Cancer Enrolled in Phase III Clinical Trials
J Connor Wells, Aven Sidhu, Keyue Ding, et al.
BMC Cancer
|
June 2, 2016
ICECREAM: randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumours
Eva Segelov, Paul Waring, Jayesh Desai, et al.
The Lancet. Gastroenterology & Hepatology
|
February 5, 2018
Napabucasin versus placebo in refractory advanced colorectal cancer: a randomised phase 3 trial
Derek J Jonker, Louise Nott, Takayuki Yoshino, et al.
Page
of 8
Search research articles
Search
Showing results (61-70 of 76) with videos related to
Sort By:
Page
of 8
The Oncologist
|
June 17, 2016
A Randomized Controlled Trial of a Nurse-Led Supportive Care Package (SurvivorCare) for Survivors of Colorectal Cancer
Michael Jefford, Karla Gough, Allison Drosdowsky, et al.
Current Problems in Cancer
|
August 23, 2020
Metastasectomy and BRAF mutation; an analysis of survival outcome in metastatic colorectal cancer
Thiru Prasanna, Rachel Wong, Timothy Price, et al.
BMC Public Health
|
August 26, 2025
Exploring the association between Cultural and Linguistic Diversity (CALD) on treatment and outcomes in pancreatic cancer: an analysis of PURPLE real-world registry data from an Australian population
Emma Sanderson, Belinda Lee, Nadia Ayres, et al.
European Urology
|
October 15, 2022
Emergence of BRCA Reversion Mutations in Patients with Metastatic Castration-resistant Prostate Cancer After Treatment with Rucaparib
Andrea Loehr, Arif Hussain, Akash Patnaik, et al.
Internal Medicine Journal
|
November 18, 2024
Real-world impact of pembrolizumab availability for deficient mismatch repair metastatic colorectal cancer
Matthew Loft, Vanessa Wong, Suzanne Kosmider, et al.
Asia-Pacific Journal of Clinical Oncology
|
July 14, 2022
Use and outcomes from neoadjuvant chemotherapy in borderline resectable pancreatic ductal adenocarcinoma in an Australasian population
Imogen Walpole, Belinda Lee, Jeremy Shapiro, et al.
Asia-Pacific Journal of Clinical Oncology
|
January 24, 2022
Impact of the evolution in RAS mutation analysis in Australian patients with metastatic colorectal cancer
Chia Yuen Chong, Azim Jalali, Hui Li Wong, et al.
The Oncologist
|
March 11, 2022
Complementary Medicine Use Amongst Patients with Metastatic Cancer Enrolled in Phase III Clinical Trials
J Connor Wells, Aven Sidhu, Keyue Ding, et al.
BMC Cancer
|
June 2, 2016
ICECREAM: randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumours
Eva Segelov, Paul Waring, Jayesh Desai, et al.
The Lancet. Gastroenterology & Hepatology
|
February 5, 2018
Napabucasin versus placebo in refractory advanced colorectal cancer: a randomised phase 3 trial
Derek J Jonker, Louise Nott, Takayuki Yoshino, et al.
Page
of 8